Haemonetics Corp. (HAE) is by far the largest global dominant blood management solutions provider. The company enjoys a truly dominant market position with huge market share on virtually all continents worldwide - 74% share in North America, 65% in Europe, 60% in Japan and 40% in the Asia/Pacific region.
In the past decade, the stock has outperformed the broader S&P 500 market (SPY) as well as its benchmark S&P healthcare index and small-cap indexes by a major margin, gaining about 350% (16.23% CAGR), which is more than double growth compared with a 110% gain (7.7% CAGR) for the broad S&P index.
I'm strongly convinced that Haemonetics has all it takes to continue in...
Only subscribers can access this article, which is part of the PRO research library covering 3,776 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: